Innovation, Pilots & Market Access

From prototype to NHS adoption

Stage-based advisory, pilot design and a clear evidence-and-procurement roadmap — so health innovations reach the patients they're built for.

The adoption gap

Why good health innovations stall

The distance between a working prototype and a product the NHS actually uses is wider, and stranger, than most founders expect. It is not crossed by building more features. It is crossed by evidence — proof that the product is clinically safe, that it does what it claims for the patients it targets, and that a buyer can justify spending on it. Innovations stall not because the idea is weak but because that evidence was never planned for, and by the time procurement asks for it, retrofitting it is slow and costly. The teams that succeed treat clinical safety, evaluation and buyer-readiness as part of the build from the beginning, not as paperwork bolted on at the end.

That is the throughline of everything we do here. We help founders define intended use precisely, design pilots that produce a credible result rather than a warm anecdote, and assemble the procurement evidence a real NHS buyer will demand. The goal is not a polished pitch; it is a defensible case that survives the questions a clinical-safety officer, an information-governance lead and a procurement panel will each ask.

The path we map

Prototype to procurement, in sequence

  1. Clinical foundations. Define intended use, clinical risk and the evidence roadmap early, with fractional leadership through Startup Clinical Advisory.
  2. Safety & standards. Establish clinical-safety and interoperability evidence via AI Validation & Clinical Safety and Digital Health & Interoperability.
  3. Pilot design. Build a pilot charter, metrics and governance — and a credible evaluation — through NHS Pilot Design & Evaluation.
  4. Evidence generation. Turn pilot data into outcomes that persuade, supported by Healthcare Data & Analytics.
  5. Buyer readiness. Assemble capability statements and bid materials with Procurement & Market-Access Readiness, guided by our NHS buyer-readiness guidance.

You do not have to take every step with us, and you rarely need them all at once. Most founders start with a single conversation about where they are and what the next obstacle is, then engage the specific capability that unblocks it.

Answers

Frequently asked questions

We are early-stage — when should we engage?

Earlier than most founders think. Defining intended use, an evidence roadmap and a clinical safety approach at seed stage avoids expensive rework before NHS pilots and procurement.

Can you help us design and run an NHS pilot?

Yes — we design the pilot charter, metrics and governance, and evaluate it credibly so the result supports a decision to scale. See NHS Pilot Design & Evaluation.

How do you support market access?

We map the routes to market that apply to you, assemble the buyer-readiness evidence (DTAC, clinical safety, DPIA) and prepare your capability statement and bid materials.

What is the difference between a pilot and an evaluation?

A pilot is the deployment; the evaluation is the evidence it generates. A pilot without a pre-agreed evaluation often produces enthusiasm but no defensible result. We design both together so the pilot answers the question a commissioner will ask before scaling.

Do you take equity instead of fees?

Our engagements are advisory work under contract, scoped and priced up front. We focus on producing the clinical, evidence and procurement assets that move your product forward, not on holding a stake in it.

Book founder office hours

Tell us your stage and goal; we'll propose a starting package.

☎ Call Get a Proposal